Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 25

PMID 39861706

Authors

Guodong Li

Shuangpeng Pu

Lisiyao You

Yuan Gao

Yuexia Zhong

Huadong Zhao

Dong Fan

Xiyan Lu

Affiliations

Soon will be listed here.

Abstract

Outer membrane vesicles (OMVs) are double-layered structures of nanoscale lipids released by gram-negative bacteria. They have the same membrane composition and characteristics as primitive cells, which enables them to penetrate cells and tissues efficiently. These OMVs exhibit excellent membrane stability, immunogenicity, safety, and permeability (which makes it easier for them to penetrate into tumour tissue), making them suitable for developing cancer vaccines and drug delivery systems. Recent studies have focused on engineering OMVs to enhance tumour-targeting capabilities, reduce toxicity, and extend circulation time in vivo. This article reviews the latest progress in OMV engineering for tumour treatment and discusses the challenges associated with the use of OMV-based antitumour therapy in clinical practice.

References

Thapa H, Ebenberger S, Schild S . The Two Faces of Bacterial Membrane Vesicles: Pathophysiological Roles and Therapeutic Opportunities. Antibiotics (Basel). 2023; 12(6). PMC: 10295235. DOI: 10.3390/antibiotics12061045. View

Wang S, Chen C, Hu M, Cheng M, Tu H, Tsai Y . Arginine-linked HPV-associated E7 displaying bacteria-derived outer membrane vesicles as a potent antigen-specific cancer vaccine. J Transl Med. 2024; 22(1):378. PMC: 11036690. DOI: 10.1186/s12967-024-05195-7. View

Zhao X, Zhao R, Nie G . Nanocarriers based on bacterial membrane materials for cancer vaccine delivery. Nat Protoc. 2022; 17(10):2240-2274. DOI: 10.1038/s41596-022-00713-7. View

Baker J, Chen L, Rosenthal J, Putnam D, DeLisa M . Microbial biosynthesis of designer outer membrane vesicles. Curr Opin Biotechnol. 2014; 29:76-84. PMC: 4171203. DOI: 10.1016/j.copbio.2014.02.018. View

Kaur R, Bhardwaj A, Gupta S . Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023; 50(11):9663-9676. DOI: 10.1007/s11033-023-08809-3. View

Senapati S, Mahanta A, Kumar S, Maiti P . Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018; 3:7. PMC: 5854578. DOI: 10.1038/s41392-017-0004-3. View

Wang S, Gao J, Wang Z . Outer membrane vesicles for vaccination and targeted drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018; 11(2):e1523. PMC: 6203682. DOI: 10.1002/wnan.1523. View

Avila-Calderon E, Ruiz-Palma M, Aguilera-Arreola M, Velazquez-Guadarrama N, Ruiz E, Gomez-Lunar Z . Outer Membrane Vesicles of Gram-Negative Bacteria: An Outlook on Biogenesis. Front Microbiol. 2021; 12:557902. PMC: 7969528. DOI: 10.3389/fmicb.2021.557902. View

Yue Y, Xu J, Li Y, Cheng K, Feng Q, Ma X . Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria. Nat Biomed Eng. 2022; 6(7):898-909. DOI: 10.1038/s41551-022-00886-2. View

10.

Nguyen J, Fernandez V, Pontrelli S, Sauer U, Ackermann M, Stocker R . A distinct growth physiology enhances bacterial growth under rapid nutrient fluctuations. Nat Commun. 2021; 12(1):3662. PMC: 8209047. DOI: 10.1038/s41467-021-23439-8. View

11.

Li Y, Cong Z, Xie L, Tang S, Ren C, Peng X . Magnetically Powered Immunogenic Macrophage Microrobots for Targeted Multimodal Cancer Therapy. Small. 2023; 19(42):e2301489. DOI: 10.1002/smll.202301489. View

12.

Marinacci B, Krzyzek P, Pellegrini B, Turacchio G, Grande R . Latest Update on Outer Membrane Vesicles and Their Role in Horizontal Gene Transfer: A Mini-Review. Membranes (Basel). 2023; 13(11). PMC: 10673008. DOI: 10.3390/membranes13110860. View

13.

Trikha P, Lee D . The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2019; 1873(1):188335. DOI: 10.1016/j.bbcan.2019.188335. View

14.

Roier S, Zingl F, Cakar F, Schild S . Bacterial outer membrane vesicle biogenesis: a new mechanism and its implications. Microb Cell. 2017; 3(6):257-259. PMC: 5348994. DOI: 10.15698/mic2016.06.508. View

15.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

16.

Li Y, Zhao R, Cheng K, Zhang K, Wang Y, Zhang Y . Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy Immune Activation and Checkpoint Inhibition. ACS Nano. 2020; 14(12):16698-16711. DOI: 10.1021/acsnano.0c03776. View

17.

Gao J, Su Y, Wang Z . Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer. Adv Drug Deliv Rev. 2022; 186:114340. PMC: 9899072. DOI: 10.1016/j.addr.2022.114340. View

18.

Luo Z, Cheng X, Feng B, Fan D, Liu X, Xie R . Engineering Versatile Bacteria-Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy. Adv Sci (Weinh). 2024; 11(33):e2400049. PMC: 11434149. DOI: 10.1002/advs.202400049. View

19.

Xie J, Li Q, Haesebrouck F, Van Hoecke L, Vandenbroucke R . The tremendous biomedical potential of bacterial extracellular vesicles. Trends Biotechnol. 2022; 40(10):1173-1194. DOI: 10.1016/j.tibtech.2022.03.005. View

20.

Rezaei Adriani R, Mousavi Gargari S, Bakherad H, Amani J . Anti-EGFR bioengineered bacterial outer membrane vesicles as targeted immunotherapy candidate in triple-negative breast tumor murine model. Sci Rep. 2023; 13(1):16403. PMC: 10541432. DOI: 10.1038/s41598-023-43762-y. View